| 2021-02 | Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still's Disease | 유대현 |
| 2012-08 | Do Patients with Elderly-Onset Rheumatoid Arthritis Have Severe Functional Disability? | 유대현 |
| 2016-08 | Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis | 유대현 |
| 2019-01 | Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study | 유대현 |
| 2013-06 | EFFECTS OF EARLY DIAGNOSIS ON DISEASE ACTIVITY AND FUNCTIONAL DISABILITY IN RHEUMATOID ARTHRITIS | 유대현 |
| 2018-12 | Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis | 유대현 |
| 2017-02 | Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | 유대현 |
| 2013-10 | Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13 | 유대현 |
| 2019-02 | Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study | 유대현 |
| 2020-09 | Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies | 유대현 |
| 2021-01 | Efficacy and safety of subcutaneous infliximab versus adalimumab etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis | 유대현 |
| 2017-08 | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis | 유대현 |
| 2017-02 | Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study | 유대현 |
| 2019-12 | Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial | 유대현 |
| 2019-07 | Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis | 유대현 |
| 2017-07 | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial | 유대현 |
| 2016-10 | Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases | 유대현 |
| 2017-08 | Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial | 유대현 |
| 2014-12 | Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial | 유대현 |
| 2017-06 | Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents | 유대현 |
